

Management of non-tuberculous mycobacterial pulmonary disease

An NTM-Net Survey led by Dr. Heinke Kunst and Dr. Akanksha Mimi Malhotra
Queen Mary University of London.

Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is considered a rare disease. The majority of respiratory and Infectious disease physicians are likely to see only a handful of patients per year.

Whilst treatment guidelines are available from the ATS/ERS/ESCMID/IDSA and BTS there is limited guidance on the infrastructure needed to manage patients with NTM disease. This includes monitoring of NTM drugs used in the treatment of NTM disease and access to advisory NTM platforms.

This survey will help to highlight and understand the variation in clinical practice across Europe which can be used to inform how service providers including clinicians can be supported to manage patients with NTM-PD.

This survey is being sent to all NTM and TBNET clinicians involved in the management of adult NTM-PD and we would be grateful for your participation. It will take approximately 10-15 minutes to complete.

We aim to close the survey by 15th **May 2024** with the aim of disseminating our findings later this year. Please do share with other colleagues in your network. We may contact you in the interim if we have received more than one response from your centre.

If you have any questions about this survey, please do not hesitate to contact Dr. Heinke Kunst on h.kunst@qmul.ac.uk

Access the survey here:

- [Click here](#)
- Follow URL: <https://forms.gle/vrpzVcfrMVp51HFt5>
- Scan QR Code



Thank you for your participation!